Page 2 - Derek Jantz News Today

CRISPR-Cas9 systems are attaining greater power and precision, and alternatives such as homing nuclease and “gene writer” systems are becoming more capable, too.

DURHAM, N.C.--(BUSINESS WIRE)--$DTIL #ARCUS--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS® genome editing platform to develop allogeneic CAR T and in vivo gene editing therapies, today announced it will present preclinical data for its chronic hepatitis B virus (...

Published: Jun 01, 2021 June 1, 2021 11:00 UTC Learnings to be Presented by Carlos Moraes, Ph.D., from University of Miami at UMDF’s Mitochondrial Medicine Symposium on June 4, 2021 Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced a new paper published online in Nature Communications that reports preclinical results using an ARCUS ...

Search jobs 01-Jun-2021  Precision BioSciences Announces New Study Published in Nature Communications Using Engineered ARCUS Nuclease to Target Mutant Mitochondrial DNA In Vivo   Learnings to be Presented by Carlos Moraes, Ph.D., from University of Miami at UMDF’s Mitochondrial Medicine Symposium on June 4, 2021 DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic ...

by WRAL TechWire — June 1, 2021 . DURHAM – Applications of the ARCUS® genome editing platform, a proprietary technology from Durham-headquartered Precision BioSciences, were studied in research now published online by Nature Communications.  The study demonstrated the technology may be used to edit outside of the nuclear genome. The paper, “Mitochondrial targeted meganuclease as a platform to eliminate mutant mtDNA in vivo” was led by Carlos T. Moraes, Ph.D., Esther Lichtenstein Prof...

Share: Precision BioSciences (NASDAQ: DTIL) shares are trading higher after the company reported its ARCUS platform showed a promising gene editing approach for transthyretin amyloidosis. "Were excited about the growing body of data demonstrating this ‘one and done approach with ARCUS, and what it may mean for transforming the treatment of rare genetic diseases in humans," said Derek Jantz, Chief Scientific Officer and co-founder of Precision BioSciences. Precision BioSciences is a genome e...

Search jobs Precision BioSciences to Participate in the Truist Securities 2021 Life Sciences Virtual Series DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced that Derek Jantz, Ph.D., Chief Scientific Officer and Co-Founder will participate in a fireside chat at the Truist Securities 20...

Share: DURHAM, N.C., April 06, 2021 (GLOBE NEWSWIRE) -- Precision BioSciences Inc. (NASDAQ:DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS ® genome editing platform, today announced a Chief Executive Officer transition plan and the initiation of a public search for a new CEO. Matt Kane, Co-Founder and Chief Executive Officer, is expected to continue in his current leadership capacity and as a board member until h...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Precision Announces 3-Year Pre-clinical Study Results Showing Long-term Durability and Safety ... Precision BiosciencesFebruary 19, 2021 GMT DURHAM, N.C., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage biotechnology company, today announced the publication of a paper in Molecular Therapy describing three-year follow-up data showing long-term stable reduc...

Feb 19, 2021 10:05am Precision BioSciences treatment could offer an alternative to fighting heart disease with PCSK9-lowering drugs like Amgen’s Repatha as well as Sanofi and Regeneron’s Praluent, researchers said. (Pixabay) Precision BioSciences was founded in 2006 to develop a genome editing technology that uses homing nucleases to make precise edits in DNA. Now, the company has preclinical evidence showing that the approach—designed as a one-time treatment—holds promise for ...